Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|13|11|1989-1998

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.11, 2015-11, pp. : 1989-1998

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of Recombinant Factor VIIa in Patients With Warfarin-Associated Intracranial Hemorrhage

By Brody David L.   Aiyagari Venkatesh   Shackleford Angela M.   Diringer Michael N.  

Neurocritical Care, Vol. 2, Iss. 3, 2005-06 ,pp. : 263-267

Humana Press, Inc

Access to resources Recommend Favorite

The Evidence behind Inhibitor Treatment with Recombinant Factor VIIa

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 13-18

Karger

Access to resources Recommend Favorite

Traumatic haemorrhage: a role for recombinant factor VIIa?

By  

ANAESTHESIA, Vol. 64, Iss. 10, 2009-10 ,pp. : 1141-1142

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful use of recombinant factor VIIa for management of severe menorrhagia in an adolescent with an acquired inhibitor of human thrombin

By  

ACTA PAEDIATRICA, Vol. 93, Iss. 6, 2004-06 ,pp. : 841-843

John Wiley & Sons Inc

Access to resources Recommend Favorite

HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours

By  

Oncology Research and Treatment, Vol. 32, Iss. 4, 2009-03 ,pp. : 168-174

Karger

Access to resources Recommend Favorite